- Home
- MIY vs EOLS Comparison
MIY vs EOLS Comparison
Compare MIY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIY | EOLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.5M | 304.0M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MIY | EOLS |
|---|---|---|
| Price | $12.55 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.40 |
| AVG Volume (30 Days) | 66.8K | ★ 686.0K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $266,274,000.00 |
| Revenue This Year | N/A | $13.57 |
| Revenue Next Year | N/A | $11.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.76 |
| 52 Week Low | $10.57 | $4.09 |
| 52 Week High | $12.77 | $14.60 |
Technical Indicators
Market Signals| Indicator | MIY | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 35.97 |
| Support Level | $10.95 | $4.09 |
| Resistance Level | $12.77 | $4.99 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 73.48 | 31.73 |
Price Performance
Historical ComparisonAbout MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.